Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Alcobra Ltd.
Type
Public company
Traded as NASDAQ: ADHD
Industry Pharmaceutical industry
Headquarters Tel Aviv, Israel
Products Metadoxine Extended Release; MDX
Website www.alcobra-pharma.com

Alcobra Ltd. is a public, specialty pharmaceutical company. The company is focused on the development of new medications to help patients with cognitive disorders, including attention deficit hyperactivity disorder (ADHD) and fragile X syndrome.

Alcobra is headquartered in Tel Aviv, Israel, and also has a U.S. office located outside of Philadelphia in Plymouth Meeting, Pennsylvania.

Alcobra was founded in 2008. In 2013, the company completed an initial public offering (IPO) and trades under the symbol “ADHD” on the NASDAQ stock exchange.

Metadoxine Extended Release (MDX) is the company’s lead investigational product candidate. Metadoxine Extended Release is a monoamine-independent modulator of GABA (gamma-aminobutyric acid) transmission. The mechanism of action does not directly affect dopamine or norepinephrine. The compound is not a psychostimulant. Metadoxine has shown no potential for abuse or addiction in studies completed to date.

Alcobra has completed two Phase II trials and one Phase III trial of Metadoxine Extended Release (MDX) in adults with ADHD. Alcobra has also completed one Phase II adolescent ADHD study of Metadoxine Extended Release (MDX). In mid-2015, Alcobra began a second Phase III trial of Metadoxine Extended Release (MDX) in adults with ADHD, called the MEASURE study.

In December 2013, the FDA granted "Orphan Drug" designation to Metadoxine in the treatment of fragile X syndrome. In June 2015, Alcobra completed a Phase II clinical trial of MDX for the treatment of adolescents and adults with fragile X syndrome. In September 2015, the FDA granted “Fast Track” status to Metadoxine Extended Release (MDX) for fragile X syndrome.

Investment goal date:
Dividends reinvested
Alcobra Ltd. ADHD report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-17
--
--
Q4 2017
2018-02-28
--
--
Q4 2017
2018-02-15
--
--
Q3 2017
2017-11-15
--
--
Q3 2017
2017-11-09
-0.1000
0.0000
Q2 2017
2017-08-11
-0.1300
-0.1300
Q1 2017
2017-05-30
-0.1300
-0.1300
Q4 2016
2017-02-15
-0.2200
-0.2200
Q3 2016
2016-11-15
-0.2800
-0.2800
Q2 2016
2016-08-30
-0.2100
-0.2100
Q1 2016
2016-05-16
-0.1800
-0.1800
Q4 2015
2016-02-17
-0.2000
-0.2000
Q3 2015
2015-11-12
-0.2000
-0.2000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
A.R.T. Advisors, LLC
177693
Broadfin Capital, LLC
1216643
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM
51000
CITADEL ADVISORS LLC
100114
D. E. Shaw & Co., Inc.
138214
FIRST REPUBLIC INVESTMENT MANAGEMENT, INC.
30000
FRANKLIN RESOURCES INC
4477500
GOLDMAN SACHS GROUP INC
44984
KINGDON CAPITAL MANAGEMENT, L.L.C.
351424
Knoll Capital Management, LP
1205498
MORGAN STANLEY
472495
Palo Alto Investors, LLC
272788
PANAGORA ASSET MANAGEMENT INC
186579
ROYCE & ASSOCIATES LLC
745055
VHCP Management, LLC
658910
Major Shareholders
Name Relationship
Total Shares
Holding stocks